| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Volume 49S Number 1
Volume 49 Number 4
Volume 49 Number 3
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 47 (2021): 751-757 |doi: 10.2306/scienceasia1513-1874.2021.094


Development of a new efficient SCAR marker for authentication of Angelica sinensis, an important traditional Chinese medicine


Hua Penga,†, Guo Chenb,c,d,†, Lilan Oub, Mao Luob,c,*, Chun Zhangb,*

 
ABSTRACT:     Angelica sinensis is a well-known traditional Chinese food and medicine that is often misused or intentionally substituted on the market. DNA samples from 6 A. sinensis cultivars and 23 related species were used to develop an efficient sequence-characterized amplified region (SCAR) marker. Eighteen inter simple sequence repeat (ISSR) primer-amplified bands were highly polymorphic (83.0%). The ISSR primer UBC826 amplified a specific fragment of 899 bp (GenBank accession no. KP789480) only from A. sinensis. The fragment was eluted, purified, cloned, and sequenced. One set of SCAR primers (UBC826 L/UBC826R), developed from the sequence information of the fragment, was found to be specific to A. sinensis and produced an amplicon of 749 bp in size. Furthermore, a new method for DNA extraction of Chinese patent medicines was developed, and 5 Chinese patent medicines containing A. sinensis were used for efficient detection of the A. sinensis-specific marker. The ISSR-based SCAR marker was developed and easily tested by PCR amplification. This marker provides an effective and precise PCR-based diagnostic method and might be conducive to raw material production and quality control for A. sinensis.

Download PDF

71 Downloads 669 Views


a Department of Tourism and Cultural Industry, Sichuan Tourism University, Chengdu 610100 China
b Department of Pharmacognosy, School of Pharmacy, Southwest Medical University, Luzhou 646000 China
c Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease of Sichuan Province, Drug Discovery Research Center, Southwest Medical University, Luzhou 646000 China
d Department of Clinical Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000 China

* Corresponding author, E-mail: luomao20050908@swmu.edu.cn, zc83good@126.com

Received 25 Dec 2020, Accepted 12 Aug 2021